01774-X/asset/3608bfb3-6329-4132-95b7-cc3434437493/main.assets/gr2_lrg.jpg)
tirzepatide surpass-5 Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Effect of Subcutaneous Tirzepatide vs
Description
and inflammation levels, including C-reactive protein (CRP)
Pre-filled syringes should be used within 24 hours to minimize the risk of contamination or degradation
Patients with a personal or family history of MTC or MEN 2 should not use tirzepatide
Step 5: Ongoing follow-up and dose adjustments Ongoing regular follow-up with your healthcare provider is essential to monitor your progress and side effects, and to potentially adjust your dose based on your bodys response
Microdosing may also reduce your cravings for fatty, spicy, salty, or high-calorie foods and prevent hedonic eating
